What is Desentum?
Desentum is a biopharmaceutical company headquartered in Espoo, Finland, established in 2011 as a spin-off from the VTT Technical Research Centre of Finland. The company's core innovation lies in a novel type of allergen immunotherapy designed to shift the immune system's response from hypersensitivity to tolerance. This is achieved through the utilization of modified hypoallergens. The scientific foundation for Desentum's work was recognized in 2013 with an EARTO Innovation Prize awarded to VTT. Further validation of its potential came in 2018 when Desentum received a substantial 1.9 million Euro grant from the Horizon 2020 SME instrument, earmarked for first-in-human clinical trials and business development initiatives.
How much funding has Desentum raised?
Desentum has raised a total of $15.5M across 3 funding rounds:
Series A
$2M
Other Financing Round
$4.5M
Unspecified
$9M
Series A (2017): $2M, investors not publicly disclosed
Other Financing Round (2019): $4.5M, investors not publicly disclosed
Unspecified (2022): $9M supported by Springvest Oyj
Key Investors in Desentum
Springvest Oyj
Springvest Oyj is a Finnish investment company known for backing growth-stage companies, likely providing strategic capital and expertise to help Desentum scale its innovative biopharmaceutical operations.
What's next for Desentum?
The recent major strategic investment and the overall enterprise-level funding context suggest Desentum is poised for significant expansion. This capital infusion is likely to accelerate its ongoing clinical development programs, potentially moving towards larger-scale human trials and further business development activities. As a company focused on inducing immune tolerance, Desentum's trajectory points towards long-term therapeutic solutions, and this latest financing round will be critical in advancing its pipeline towards potential commercialization or further strategic partnerships within the biopharmaceutical sector.
See full Desentum company page
